VIDEO: Olaparib may offer chemotherapy alternative

ByHalle Moore, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In this video, Halle Moore, MD, director of Breast Medical Oncology in the Department of Hematology and Oncology at Cleveland Clinic Taussig Cancer Institute, spoke with Healio about presentations in breast cancer at the virtual ASCO Annual Meeting.

A study Moore found interesting explored extended indications for the PARP inhibitor Olaparib, which examined additional germline mutations somatic mutations and whether Olaparib was effective in those conditions.

“What they found was that another mutation, called PALB2...was also associated with a benefit to the PARP inhibitor Olaparib. In addition, those patients who had not germline but somatic BRCA mutations also benefited from the Olaparib. This gave some additional indications for using this treatment, which is a great alternative to chemotherapy for many patients.”

References

• Tung, MN, et al. Abstract 1002. Presented at: ASCO20 Virtual Scientific Program; May 29-31, 2020.